CN101918369B - 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 - Google Patents
治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 Download PDFInfo
- Publication number
- CN101918369B CN101918369B CN200880116208.2A CN200880116208A CN101918369B CN 101918369 B CN101918369 B CN 101918369B CN 200880116208 A CN200880116208 A CN 200880116208A CN 101918369 B CN101918369 B CN 101918369B
- Authority
- CN
- China
- Prior art keywords
- tert
- butyl
- phenyl
- dioxo
- methanesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C(N1*)=O)=C(*)NC1=O Chemical compound *C(C(N1*)=O)=C(*)NC1=O 0.000 description 21
- KLRKUHAYVXPMPR-UHFFFAOYSA-N CC(C)(C)c(cc(cc1C)N(C(N2)O)C=CC2O)c1OC Chemical compound CC(C)(C)c(cc(cc1C)N(C(N2)O)C=CC2O)c1OC KLRKUHAYVXPMPR-UHFFFAOYSA-N 0.000 description 1
- TZOFFLZEYSSPKZ-VOTSOKGWSA-N CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C/c(ccc(NC/[O]=S/C)c2)c2OC)c1O Chemical compound CC(C)(C)c1cc(N(CCC(N2)=O)C2=O)cc(/C=C/c(ccc(NC/[O]=S/C)c2)c2OC)c1O TZOFFLZEYSSPKZ-VOTSOKGWSA-N 0.000 description 1
- DYPXHCGOGZFKGJ-JFVNZWERSA-N CC(C)CCNCc1cc(NS(C)(=O)=O)ccc1/C=C/c(cc(cc1C(C)(C)C)N(C=CCOCN2)C2=O)c1OC Chemical compound CC(C)CCNCc1cc(NS(C)(=O)=O)ccc1/C=C/c(cc(cc1C(C)(C)C)N(C=CCOCN2)C2=O)c1OC DYPXHCGOGZFKGJ-JFVNZWERSA-N 0.000 description 1
- AQKYCMMUMPTELX-UHFFFAOYSA-O CC(CCN1c2cc(C=Cc(cc3)ccc3[NH3+])cc(C(C)(C)C)c2)NC1=O Chemical compound CC(CCN1c2cc(C=Cc(cc3)ccc3[NH3+])cc(C(C)(C)C)c2)NC1=O AQKYCMMUMPTELX-UHFFFAOYSA-O 0.000 description 1
- AVVSJWUWBATQBX-UHFFFAOYSA-N CC1(OC(C)(C2)OC3(C)C1)OC2(C)P3c1ccccc1 Chemical compound CC1(OC(C)(C2)OC3(C)C1)OC2(C)P3c1ccccc1 AVVSJWUWBATQBX-UHFFFAOYSA-N 0.000 description 1
- RMOODACIVICURL-ZZXKWVIFSA-N COc(c(/C=C/c(cc1)ccc1NS(C)(=O)=O)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccncc1 Chemical compound COc(c(/C=C/c(cc1)ccc1NS(C)(=O)=O)cc(N(C=CC(N1)=O)C1=O)c1)c1-c1ccncc1 RMOODACIVICURL-ZZXKWVIFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510508424.3A CN105294569A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN201610091594.0A CN105693626A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97288707P | 2007-09-17 | 2007-09-17 | |
| US60/972,887 | 2007-09-17 | ||
| US9679408P | 2008-09-13 | 2008-09-13 | |
| US61/096,794 | 2008-09-13 | ||
| PCT/US2008/076594 WO2009039135A1 (en) | 2007-09-17 | 2008-09-17 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610091594.0A Division CN105693626A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN201510508424.3A Division CN105294569A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101918369A CN101918369A (zh) | 2010-12-15 |
| CN101918369B true CN101918369B (zh) | 2016-02-24 |
Family
ID=40091991
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880116208.2A Expired - Fee Related CN101918369B (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN201510508424.3A Pending CN105294569A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN201610091594.0A Pending CN105693626A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510508424.3A Pending CN105294569A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN201610091594.0A Pending CN105693626A (zh) | 2007-09-17 | 2008-09-17 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8178548B2 (enExample) |
| EP (3) | EP2548873A1 (enExample) |
| JP (1) | JP5726527B2 (enExample) |
| CN (3) | CN101918369B (enExample) |
| AT (1) | ATE512954T1 (enExample) |
| CA (1) | CA2699989C (enExample) |
| DK (1) | DK2203430T3 (enExample) |
| HR (1) | HRP20110632T1 (enExample) |
| MX (1) | MX2010002904A (enExample) |
| PL (1) | PL2203430T3 (enExample) |
| PT (1) | PT2203430E (enExample) |
| RU (1) | RU2542099C2 (enExample) |
| WO (1) | WO2009039135A1 (enExample) |
| ZA (1) | ZA201002690B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693626A (zh) * | 2007-09-17 | 2016-06-22 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2543620C2 (ru) * | 2007-09-17 | 2015-03-10 | Эббви Бахамаз Лтд. | Производные урацила или тимина для лечения гепатита с |
| PL2203431T3 (pl) | 2007-09-17 | 2012-01-31 | Abbvie Bahamas Ltd | Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania |
| ES2383273T3 (es) | 2008-07-23 | 2012-06-19 | F. Hoffmann-La Roche Ag | Compuestos heterocíclicos antivíricos |
| CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| RU2011121511A (ru) | 2008-10-30 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | Гетероциклические антивирусные производные арилпиридона |
| SG172778A1 (en) | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| TW201035083A (en) | 2009-03-06 | 2010-10-01 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| JP5744003B2 (ja) * | 2009-03-24 | 2015-07-01 | アッヴィ・バハマズ・リミテッド | 抗ウイルス化合物を調製する方法 |
| WO2010122082A1 (en) * | 2009-04-25 | 2010-10-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| WO2010149598A2 (en) | 2009-06-24 | 2010-12-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
| BR112012005616A2 (pt) | 2009-09-21 | 2016-06-21 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| EP2501679A1 (en) * | 2009-11-21 | 2012-09-26 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| CN102753173A (zh) * | 2009-12-18 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | Hcv组合疗法 |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| JP5651239B2 (ja) * | 2010-07-07 | 2015-01-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 複素環式抗ウイルス化合物 |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| AU2011278927B2 (en) | 2010-07-16 | 2015-05-21 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| BR112013001138A2 (pt) | 2010-07-16 | 2016-07-05 | Abbvie Inc | ligantes de fosfina para reações catalíticas |
| TWI558400B (zh) * | 2011-03-18 | 2016-11-21 | 艾伯維有限公司 | 苯基尿嘧啶化合物之調配物 |
| US8989328B2 (en) * | 2013-03-14 | 2015-03-24 | Qualcomm Incorporated | Systems and methods for serial communication |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP7041140B2 (ja) * | 2016-11-01 | 2022-03-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換された６員アリール又はヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| EP4032006A4 (en) | 2019-09-16 | 2022-11-23 | Visa International Service Association | SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR VERIFYING A MAP IMAGE |
| EP3819006A1 (en) * | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111018910A (zh) * | 2019-12-05 | 2020-04-17 | 上海应用技术大学 | 一种铜催化合成含芳环α-羟基膦酸酯的方法 |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| ATE169915T1 (de) * | 1990-02-15 | 1998-09-15 | Takeda Chemical Industries Ltd | Pyrimidindionderivate, deren herstellung und verwendung |
| NL9001075A (enExample) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| MXPA02005564A (es) | 1999-12-06 | 2002-09-02 | Hoffmann La Roche | 4-pirimidinil-n-acil-l.fenilalaninas. |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167955A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| RU2543620C2 (ru) | 2007-09-17 | 2015-03-10 | Эббви Бахамаз Лтд. | Производные урацила или тимина для лечения гепатита с |
| MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
| PL2203431T3 (pl) | 2007-09-17 | 2012-01-31 | Abbvie Bahamas Ltd | Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania |
| ES2383273T3 (es) | 2008-07-23 | 2012-06-19 | F. Hoffmann-La Roche Ag | Compuestos heterocíclicos antivíricos |
-
2008
- 2008-09-17 MX MX2010002904A patent/MX2010002904A/es active IP Right Grant
- 2008-09-17 CN CN200880116208.2A patent/CN101918369B/zh not_active Expired - Fee Related
- 2008-09-17 WO PCT/US2008/076594 patent/WO2009039135A1/en not_active Ceased
- 2008-09-17 DK DK08831558.5T patent/DK2203430T3/da active
- 2008-09-17 EP EP12185550A patent/EP2548873A1/en not_active Withdrawn
- 2008-09-17 PL PL08831558T patent/PL2203430T3/pl unknown
- 2008-09-17 CA CA2699989A patent/CA2699989C/en not_active Expired - Fee Related
- 2008-09-17 US US12/212,315 patent/US8178548B2/en active Active
- 2008-09-17 JP JP2010525104A patent/JP5726527B2/ja active Active
- 2008-09-17 HR HR20110632T patent/HRP20110632T1/hr unknown
- 2008-09-17 CN CN201510508424.3A patent/CN105294569A/zh active Pending
- 2008-09-17 RU RU2010114826/04A patent/RU2542099C2/ru active
- 2008-09-17 EP EP08831558A patent/EP2203430B1/en not_active Not-in-force
- 2008-09-17 EP EP11163527A patent/EP2377854A1/en not_active Withdrawn
- 2008-09-17 PT PT08831558T patent/PT2203430E/pt unknown
- 2008-09-17 AT AT08831558T patent/ATE512954T1/de active
- 2008-09-17 CN CN201610091594.0A patent/CN105693626A/zh active Pending
-
2010
- 2010-04-16 ZA ZA2010/02690A patent/ZA201002690B/en unknown
-
2012
- 2012-04-06 US US13/441,528 patent/US8986740B2/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Raffaele De Francesco,et al.,.Approaching a new era for hepatitis C virus therapy:inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase.《Antiviral Research》.2003,第58卷(第1期),1-16. * |
| Raffaele De Francesco,et al.,.Challenges and successes in developing new therapies for hepatitis C.《NATURE》.2005,第436卷953-960. * |
| Uwe Koch,et al.,.2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase:Discovery,SAR,Modeling,and Mutagenesis.《Journal of Medicinal Chemistry》.2006,第49卷(第5期),1693-1705. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693626A (zh) * | 2007-09-17 | 2016-06-22 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8986740B2 (en) | 2015-03-24 |
| JP2010539188A (ja) | 2010-12-16 |
| CA2699989C (en) | 2014-03-25 |
| CN105294569A (zh) | 2016-02-03 |
| MX2010002904A (es) | 2010-06-02 |
| PL2203430T3 (pl) | 2011-12-30 |
| HRP20110632T1 (hr) | 2011-10-31 |
| US20120189580A1 (en) | 2012-07-26 |
| RU2542099C2 (ru) | 2015-02-20 |
| CA2699989A1 (en) | 2009-03-26 |
| EP2377854A1 (en) | 2011-10-19 |
| PT2203430E (pt) | 2011-09-02 |
| JP5726527B2 (ja) | 2015-06-03 |
| DK2203430T3 (da) | 2011-09-26 |
| RU2010114826A (ru) | 2011-10-27 |
| EP2203430A1 (en) | 2010-07-07 |
| EP2548873A1 (en) | 2013-01-23 |
| ZA201002690B (en) | 2015-12-23 |
| ATE512954T1 (de) | 2011-07-15 |
| US8178548B2 (en) | 2012-05-15 |
| HK1145839A1 (en) | 2011-05-06 |
| CN105693626A (zh) | 2016-06-22 |
| EP2203430B1 (en) | 2011-06-15 |
| CN101918369A (zh) | 2010-12-15 |
| US20090176784A1 (en) | 2009-07-09 |
| WO2009039135A1 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101918369B (zh) | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 | |
| CN102746239B (zh) | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 | |
| CN101842360B (zh) | 抗感染嘧啶及其用途 | |
| ES2365650T3 (es) | N-fenil-dioxo-hidroxipirimidinas útiles como inhibidores del virus de la hepatitis c (vhc). | |
| AU2014280939B2 (en) | Uracil or thymine derivative for treating hepatitis C | |
| HK1182090A (en) | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors | |
| HK1145839B (en) | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors | |
| HK1156033B (en) | Anti-infective pyrimidines and uses thereof | |
| HK1189590B (en) | Anti-infective pyrimidines and uses thereof | |
| HK1147256B (en) | Uracil or thymine derivative for treating hepatitis c | |
| HK1189590A (en) | Anti-infective pyrimidines and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ABBOTT HOSPITAL CO., LTD. Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG Effective date: 20131213 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Bahamas Nassau Applicant after: AbbVie Inc. Address before: Bahamas Nassau Applicant before: Abbott Laboratories Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ABBOTT HOSPITAL CO., LTD. TO: ABBVIE BAHAMAS B.V. |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20131213 Address after: Bahamas Nassau Applicant after: Abbott Laboratories Ltd. Address before: Illinois State Applicant before: ABBOTT LABORATORIES |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160224 Termination date: 20160917 |